More Clinical Articles


Putting a Dent in Neglected Diseases

Deirdre Coleman, (Sep 3, 2014)

Steve Jobs once said, “We’re here to put a dent in the universe”. We talk to Flemish researcher, Koen Andries, who has succeeded in putting a considerable dent in the progression of multi-drug resistant TB. Here, he discusses the deadly gap that persists in neglected disease drug development.

New Study Insights: What Works Where for Patient Recruitment and Retention Tools and Techniques

Chris Frega, (Sep 2, 2014)

Patient recruitment and retention has continued to be one of the largest challenges in clinical development for biopharma companies, with most studies experiencing start-up delays and/or completing late.

3 Questions to Joel Beetsch, Vice President of Patient Advocacy, Celgene

Nick de Cent, (Aug 29, 2014)

eyeforpharma asked Joel Beetsch, Vice President of Patient Advocacy at Celgene, 3 questions about how patient centricity is changing the landscape of clinical trials.

Why drugs fail to get approved

Zuzanna Fimińska, (Aug 25, 2014)

Over 12 years, 50%new molecular entities (NMEs) failed to obtain approval when first submitted to the FDA. Some new applications were rejected because of inadequate drug performance, other, however, failed because of, what looks at first glance as, sloppiness.

Using Data to Design and Implement Patient-Centric Enrollment and Retention Strategies

Scott Connor, (Aug 22, 2014)

What sponsor doesn’t want more successful clinical trials – on time, on budget, with quality data?

Can we harness “big data” effectively?

Nick de Cent, (Aug 13, 2014)

From new healthcare products to the way we conduct clinical trials, “big data” is poised to transform the pharma landscape. But first, we’ve got to work out how to use it effectively – especially in the best interests of the patient, writes Nick de Cent.

Empowering Patients

Ulrich Neumann, (Aug 5, 2014)

The need for disruptive innovation in pharma has reached a precipice. In order to compete in the era of stratified medicine, cost-effectiveness considerations, and overall patient empowerment, the industry must rethink every aspect of the drug development continuum.

Some Front Row Perspectives on Patient Centricity

Paul Ivsin, (Aug 4, 2014)

"And that is quite likely the biggest barrier to advocates of patient centered clinical trials today: not that they will be resisted, but that their message will be co-opted and their efforts shunted into high-visibility but low-impact initiatives".

The Patient Centricity “Fad” and the Token Patient

Paul Ivsin, (Jul 30, 2014)

Embracing the concept of patient centricity does not guarantee substantial patient-centred change, particularly in the area of patient-centred trials.

Management of Patient Adherence in Clinical Trials Using Electronic Monitoring

John Musaus, (Jul 25, 2014)

Automatic adherence measurement through electronic compilation of drug dosing histories plays a key role in achieving and maintaining patients’ adherence to prescribed therapies.